321 related articles for article (PubMed ID: 18668133)
41. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological characteristics of myelodysplastic syndromes with del(5q) in Taiwan.
Yang CF; Hsu CY; Hsiao LT; Chen SW; Chuang SS
Malays J Pathol; 2023 Dec; 45(3):405-416. PubMed ID: 38155382
[TBL] [Abstract][Full Text] [Related]
43. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.
Garderet L; Ziagkos D; van Biezen A; Iacobelli S; Finke J; Maertens J; Volin L; Ljungman P; Chevallier P; Passweg J; Schaap N; Beelen D; Nagler A; Blaise D; Poiré X; Yakoub-Agha I; Lenhoff S; Craddock C; Schots R; Rambaldi A; Sanz J; Jindra P; Mufti GJ; Robin M; Kröger N
Biol Blood Marrow Transplant; 2018 Mar; 24(3):507-513. PubMed ID: 29196078
[TBL] [Abstract][Full Text] [Related]
44. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
[TBL] [Abstract][Full Text] [Related]
45. The IPSS-R has prognostic impact in untreated patients with MDS del(5q).
Kaivers J; Lauseker M; Hildebrandt B; Fenaux P; Pfeilstöcker M; Valent P; Platzbecker U; Latagliata R; Oliva EN; Xicoy B; Götze K; Ganster C; Haase D; Bug G; Kündgen A; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Sep; 72():27-33. PubMed ID: 30075323
[TBL] [Abstract][Full Text] [Related]
46. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
[TBL] [Abstract][Full Text] [Related]
47. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
[TBL] [Abstract][Full Text] [Related]
48. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
Cermák J; Michalová K; Brezinová J; Zemanová Z
Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
[TBL] [Abstract][Full Text] [Related]
49. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
Pitchford CW; Hettinga AC; Reichard KK
Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
[TBL] [Abstract][Full Text] [Related]
50. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype.
Patnaik MM; Hanson CA; Hodnefield JM; Knudson R; Van Dyke DL; Tefferi A
Leukemia; 2011 Feb; 25(2):266-70. PubMed ID: 21072042
[TBL] [Abstract][Full Text] [Related]
51. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
Jädersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Göhring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellström-Lindberg E; Mufti GJ
J Clin Oncol; 2011 May; 29(15):1971-9. PubMed ID: 21519010
[TBL] [Abstract][Full Text] [Related]
52. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
[TBL] [Abstract][Full Text] [Related]
53. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
54. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.
Slovak ML; O'Donnell M; Smith DD; Gaal K
Cancer Genet Cytogenet; 2009 Sep; 193(2):78-85. PubMed ID: 19665067
[TBL] [Abstract][Full Text] [Related]
55. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
Mallo M; Cervera J; Schanz J; Such E; García-Manero G; Luño E; Steidl C; Espinet B; Vallespí T; Germing U; Blum S; Ohyashiki K; Grau J; Pfeilstöcker M; Hernández JM; Noesslinger T; Giagounidis A; Aul C; Calasanz MJ; Martín ML; Valent P; Collado R; Haferlach C; Fonatsch C; Lübbert M; Stauder R; Hildebrandt B; Krieger O; Pedro C; Arenillas L; Sanz MÁ; Valencia A; Florensa L; Sanz GF; Haase D; Solé F
Leukemia; 2011 Jan; 25(1):110-20. PubMed ID: 20882045
[TBL] [Abstract][Full Text] [Related]
56. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Delaunay J; Banos A; Blanc M; Vey N; Schmidt A; Visanica S; Eclache V; Turlure P; Beyne-Rauzy O; Guerci A; Delmer A; de Botton S; Rea D; Fenaux P; Adès L
Leuk Res; 2011 Nov; 35(11):1444-8. PubMed ID: 21715006
[TBL] [Abstract][Full Text] [Related]
57. Clonal monosomy 7 and 5q--in a child with myelodysplastic syndrome.
Chantrain C; Vermylen C; Michaux L; Brichard B; Cornu G
Pediatr Hematol Oncol; 2000 Sep; 17(6):505-9. PubMed ID: 10989472
[TBL] [Abstract][Full Text] [Related]
58. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
Braun T; de Botton S; Taksin AL; Park S; Beyne-Rauzy O; Coiteux V; Sapena R; Lazareth A; Leroux G; Guenda K; Cassinat B; Fontenay M; Vey N; Guerci A; Dreyfus F; Bordessoule D; Stamatoullas A; Castaigne S; Terré C; Eclache V; Fenaux P; Adès L
Leuk Res; 2011 Jul; 35(7):863-7. PubMed ID: 21396711
[TBL] [Abstract][Full Text] [Related]
59. [The clinical features, cytogenetic characteristics and survival analysis of 550 myelodysplastic syndromes in a single center].
Zhang TT; Sun AN; Pan JL; Wu DP; Qiu HY; Tang XW; Miao M; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):864-869. PubMed ID: 27801317
[TBL] [Abstract][Full Text] [Related]
60. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
